|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We performed a nonblinded, randomized controlled trial of 78 children with CD (6-18 years old; 29% female; mean age, 14.3 ± 2.6 years) who had not received prior treatment with a biologic agent but had responded to adalimumab induction therapy, under scheduled monitoring of clinical and biologic measures (based on clinical factors and levels of C-reactive protein and fecal calprotectin), at pediatric gastroenterology units in Israel from July 2015 through December 2018.
|
31194979 |
2019 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the characteristics of disagreement, and analyzed the relationships with the Crohn's Disease Activity Index (CDAI) and C-reactive protein.
|
31541367 |
2020 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined negative LNs in relation to the local and systemic immune response, including percentage carcinoma, neutrophil and lymphocyte infiltration, Crohn's-like reaction, neutrophil to lymphocyte ratio, platelets, and C-reactive protein (CRP).
|
29950897 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data from the ImageKids study to determine associations among mucosal, transmural healing and levels of calprotectin and C-reactive protein in children with CD.
|
29501599 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TRIM22 is also associated with antiviral and mycobacterial effectors and markers of inflammation, such as fecal calprotectin, C-reactive protein, and Crohn's disease activity index scores.
|
26836588 |
2016 |
|
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this is the first report that supports the association of SNPs in ATG5 and CRP genes with response to adalimumab therapy in Crohn's disease.
|
27096233 |
2016 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the association between 18F-FDG (Fluorodeoxyglucose) PET (positron emission tomography)/MRE (magnetic resonance enterography) metrics with the inflammatory biomarkers fecal calprotectin and C-reactive protein (CRP) in patients with Crohn's disease (CD).
|
29097934 |
2017 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine the efficacy of faecal calprotectin (FC) and C-reactive protein (CRP) as predictors of SBCE findings in suspected and known CD.
|
29466790 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study did not report on clinical response, CRP, quality of life or withdrawal due to AEs.One small study (N= 50) compared cannabis oil (15% cannabidiol and 4% THC) to placebo in participants with active CD.
|
30407616 |
2018 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cytokines and CRP may serve as additional biomarkers for determining disease activity and evaluating treatment response in CD.
|
29466406 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The variables used were Crohn's disease activity index (CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
|
31689999 |
2019 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The SES-CD correlated closest with FC (r = 0.503), followed by CRP (r = 0.461), ESR (0.377) and the CDAI (r = 0.320).
|
28512287 |
2017 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to characterize pharmacokinetics (PK) of PF-04236921, a novel anti-interleukin-6 monoclonal antibody, and its pharmacokinetic/pharmacodynamic (PK/PD) relationship on serum C-reactive protein (CRP) in healthy volunteers and patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Crohn's disease (CD).
|
29776017 |
2018 |
|
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The proportions of Crohn's disease having a positive clinical or biological response were not statistically different among the various genotypes of CRP polymorphisms.
|
16344720 |
2006 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The primary end points were time to clinical relapse (CD activity index of >150 with an increase of >70 points) and serological relapse (abnormal elevation of C-reactive protein).
|
29257147 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The methodological quality of this study with respect to reliability was 'good'.With respect to validity, correlation estimates between various histological scoring systems and Crohn's disease activity as measured by objective markers of inflammation (including C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin); endoscopic disease activity scores; clinical disease activity scores; and quality of life questionnaires were reported.
|
28731502 |
2017 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The correlations of elafin expression with erythrocyte sedimentation rate and C-reactive protein were determined by Spearman's correlation analysis and with clinical disease activity indices (Best Crohn's Disease Activity Index and modified Mayo scores) by Pearson's correlation analysis.
|
29084078 |
2017 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The correlation of granulomatous inflammation with C-reactive protein was expanded to 86 treatment-naïve CD cases.
|
22699834 |
2012 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined monitoring of CDAI, CRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with CD.
|
31148906 |
2019 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The clinical response to treatment was assessed using the Crohn's disease activity index and C-reactive protein (CRP) values.
|
30874986 |
2019 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease.
|
12190096 |
2002 |
|
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the diagnostic performance as well as the relationship of C-reactive protein (CRP) and Crohn's Disease Activity Index (CDAI) with small bowel capsule endoscopy's (SBCE) inflammation scoring index, the Lewis Score (LS).
|
29697457 |
2018 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to determine the prevalence of the tumor necrosis factor alpha (TNF-alpha) promoter polymorphisms at positions -238 and -308, and to measure the serum CRP levels in CD and UC patients and in a healthy population.
|
12811429 |
2003 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to assess the correlation between SAA, inflammatory cytokines, and mucosal inflammation in patients with Crohn's disease and to investigate whether this marker might be useful in patients who do not have elevated C-reactive protein (CRP) levels despite having active disease.
|
27930409 |
2017 |
|
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to explore the correlations between LS and clinical disease activity indices, CRP, SBTT in pediatric, and adult patients with small bowel CD.Retrospective, single-center study on consecutive inpatients with established small bowel CD was conducted.
|
28816962 |
2017 |